At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

Nagendrakumar B Singanallur[1†], Petrus Jansen van Vuren[1†], Alexander J McAuley[1†], Matthew
P Bruce[1], Michael J Kuiper[2], Stella M Gwini[3], Shane Riddell[1], Sarah Goldie[1], Trevor W Drew[1],
Kim R Blasdell[1], Mary Tachedjian[1], Shruthi Mangalaganesh[1,4], Simran Chahal[1], Leon Caly[5],
Julian D Druce[5], Jennifer A Juno[6], Stephen J Kent[6], Adam K Wheatley[6], Seshadri Vasan[1,7]*

[1]Commonwealth Scientific and Industrial Research Organisation (CSIRO) Australian Centre for
Disease Preparedness (ACDP), Geelong, VIC 3220, Australia
[2]Data61, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Docklands, VIC
3008, Australia
[3]University Hospital Geelong, Barwon Health, Geelong, VIC 3220, Australia
[4]Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3168, Australia
[5]Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for
Infection and Immunity, Melbourne, VIC 3000, Australia
[6]Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty
Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
[7]Department of Health Sciences, University of York, York, YO10 5DD, United Kingdom
[†]These authors have contributed equally to this work and share first authorship

*Correspondence:

Prof. Seshadri S. Vasan, **vasan.vasan@csiro.au**; **orcid.org/0000-0002-7326-3210**

Abstract

Plasma samples taken at different time points from donors who received either AstraZeneca
(Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19)
vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern
and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50%
neutralizing antibody titres (NT_{50}) against Delta and VIC31 at 6 months compared to 2 weeks after
the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of
Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres
below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks
after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold
lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender
were not found to significantly impact our results. These observations indicate that vaccine matching
may be needed, and that at least a third dose of these vaccines is necessary to generate sufficient
neutralising antibodies against emerging variants of concern, especially Omicron, amidst the
challenges of ensuring vaccine equity worldwide.

Keywords: AlphaFold; BA.1.1; biomolecular modelling; COVID-19; neutralising antibody
titres; SARS-CoV-2; Spike protein; variants of concern; vaccines; vaccine matching

Introduction

The novel coronavirus disease-19 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in circa 420 million cases and 6 million deaths and is yet to be brought under control [1]. Only 14.2 vaccine doses have been administered per 100 people in 'low-income countries'; for 'lower middle income countries' excluding India the number is 81.6 doses per 100 people [2]. Thus, half the world's population is still receiving the first dose of a COVID-19 vaccine and is very vulnerable. Although vaccines can reduce the likelihood of infection, re-infection and disease severity in individuals, and to an extent community transmission, the continuous emergence of SARS-CoV-2 variants of concern (VOC) has frustrated global response efforts and highlighted the importance of continued assessment of vaccine efficacy. The World Health Organization has declared 5 VOC to date, viz. Alpha (18 December 2020), Beta (18 December 2020), Gamma (11 January 2021), Delta (11 May 2021), Omicron (26 November 2021), of which Delta and Omicron are currently of the greatest concern and two variants of interest (VOI) viz. Lambda (14 June 2021) and Mu (30 August 2021) [3].

While studies on T-cell responses will provide a more holistic picture of vaccine-induced efficacy, assessment of neutralising antibody reactivity against emerging VOC, such as Omicron (B.1.1.529, referred to as BA.1 henceforth), can help inform near-term public health response. This is especially important for the vaccines manufactured by Pfizer, Moderna, and AstraZeneca, as one or more of these three are approved in 192 countries (which does not include the People's Republic of China), representing 77% of the world's population [2]. In this study we have assessed the ability of human plasma samples collected from vaccinated donors at different timepoints to neutralise the current two most globally-prevalent VOC (Delta and Omicron) in comparison with a reference isolate used in previous studies (VIC31; [4]). We have also bolstered our interpretation using *in silico* modelling of the respective Spike proteins and outlined our thoughts on future follow-up studies.

Materials and Methods

SARS-CoV-2 Stock Generation and Characterisation

Three SARS-CoV-2 isolates, VIC31 (hCoV-19/Australia/VIC31/2020 containing D614G mutation), Delta variant of concern (hCoV-19/Australia/VIC18440/2021), and Omicron BA.1.1 variant of concern (hCoV-19/Australia/VIC28585/2021) were provided by the Victorian Infectious Diseases Reference Laboratory (VIDRL; Melbourne, Australia). Virus stocks were propagated and titrated in Vero E6 cells (American Type Culture Collection (ATCC), Manassas, VA, USA) prior to use as previously outlined in [5]. Briefly, VeroE6 cells were grown in 150 cm^2 flasks in Dulbecco's Modified Eagle Medium (DMEM) containing 10% heat-inactivated foetal bovine serum (FBS), 2mM GlutaMAX supplement, 100U/mL penicillin, and 100 µg/mL streptomycin (all components from ThermoFisher Scientific; Scoresby, VIC, Australia) until >80% confluent. Virus isolates were diluted 1:100 in DMEM (containing 2% FBS, 2mM GlutaMAX supplement, 100U/mL penicillin, and 100 µg/mL streptomycin), and 5 mL was used to inoculate Vero E6 cells for 1 hr at 37°C/5% CO_2 before additional media was added to the flask. The flasks were incubated at 37°C/5% CO_2 for 48 h (for VIC31 and Delta) or 72 hr (for Omicron) before supernatant was clarified at 2,000 x *g* for 10 min, and harvested and stored in 1 mL aliquots at -80 °C.

Identity of virus stocks were confirmed by next-generation sequencing using a MiniSeq platform (Illumina, Inc; San Diego, CA, USA). In brief, 100 µL cell culture supernatant from infected Vero E6 cells was combined with 300 µL TRIzol reagent (Thermo Fisher Scientific) and

RNA was purified using a Direct-zol RNA Miniprep kit (Zymo Research; Irvine, CA, USA). Purified
RNA was further concentrated using an RNA Clean-and-Concentrator kit (Zymo Research), followed
by quantification on a DeNovix DS-11 FX Fluorometer. RNA was converted to double-stranded
cDNA, ligated then isothermally amplified using a QIAseq FX single cell RNA library kit (Qiagen,
Hilden, Germany). Fragmentation and dual-index library preparation was conducted with an Illumina
DNA Prep, Tagmentation Library Preparation kit. Average library size was determined using a
Bioanalyser (Agilent Technologies; San Diego, CA, USA) and quantified with a Qubit 3.0
Fluorometer (Invitrogen; Carlsbad, CA, USA). Denatured libraries were sequenced on an Illumina
MiniSeq using a 300-cycle Mid-Output Reagent kit as per the manufacturer's protocol. Paired-end
Fastq reads were trimmed for quality and mapped to the published sequence for the SARS-CoV-2
reference isolate Wuhan-Hu-1 (RefSeq: NC_045512.2) using CLC Genomics Workbench version 21
from which consensus sequences were generated. Stocks were confirmed to be free from
contamination by adventitious agents by analysis of reads that did not map to SARS-CoV-2 or cell-
derived sequences.

Human Plasma Samples

Blood samples in EDTA blood collection tubes (BD Biosciences, Australia) were collected
from healthy volunteers, aged between 25-70 (both female and male), who received COVID-19
vaccine manufactured by either AstraZeneca (Vaxzevria/AZD1222; University of Oxford-
AstraZeneca, Oxford/Cambridge, UK), Pfizer (Comirnaty/BNT162b2; BioNTech-Pfizer, Brooklyn,
New York, USA), or Moderna (Spikevax/mRNA-1273; Moderna Inc, Cambridge, MA, USA) (**Table
1**). AstraZeneca vaccine was advised for the age group >60 [**6**]. Plasma was separated and stored at -
70°C until use. The study protocols were approved by institutional ethics committees of the Peter
Doherty Institute, Melbourne Australia [University of Melbourne Central Human Research Ethics
Committee (2021-21198-15398-3)] and the CSIRO (CSIRO Human Research Ethics Committee ID
2021_123_RR). Biosafety protocols for handling the human samples and the infectious agents were
approved by the Institutional Biosafety Committee of ACDP, Geelong before infectious work
commenced. Blood samples were collected on the day of vaccination (baseline; pre-1st dose) and 2
weeks post second dose (2wk-2nd dose) for all the vaccine groups and after six months of 2nd dose
(6mo-2nd dose) and two weeks post third dose (2wk-3rd dose) for the Pfizer group.

Live-Virus Neutralisation Assays

Virus neutralization assays (VNT) were carried out using Vero E6 cells as described previously
[**5**]. Briefly, each plasma sample for the three vaccines was diluted 1:10 in Dulbecco's Phosphate
Buffered Saline (DPBS; Thermo Fisher Scientific, Waltham, MA, USA) in a deep-well plate,
followed by a two-fold serial dilution up to 1:1,280. The dilution series for each plasma sample was
dispensed into triplicate columns of a 96-well plate (one plate per isolate), for a total volume of 50 µl
per well. For the plasma-containing wells, 50 µl virus diluted in DMEM (Thermo Fisher Scientific,
Waltham, MA, USA) containing 2% FBS, 2mM GlutaMAX supplement, 100U/mL penicillin, and
100 µg/mL streptomycin to contain approximately 100 $TCID_{50}$ (checked by back-titration) was added
to each well. The plates were incubated at 37°C/5% CO_2 for 1 h to allow neutralization complexes to
form between the antibodies present in the plasma and the virus. A positive control serum was
included to confirm the reproducibility of the assay. At the end of the incubation, 100 µl VeroE6
cells were added to each well and the plates were returned to the incubator for 4 days. Each well was
scored for the presence of viral CPE, readily discernible on Day 4 post-infection. NT_{50} neutralization
titres calculated using the Spearman–Karber formula [**7**] and transformed to log2 values for analysis.

Replicates that did not show neutralisation at 1:10 were scored <1:10 dilution and assigned a value
1:5 for statistical analysis in line with the current best practice [**8**].

In silico Modelling

Molecular models were made of the trimeric Omicron Spike protein from residues 13 to 1160
(omitting the transmembrane domain) consistent with variant BA.1.1 and including glycosylation to
visualize structural changes from the original strain. 'AlphaFold' [**9**] was used to reconstruct the N-
terminal domain due to insertions and deletions. Models were built to include the 'up' and 'down'
conformations of the Receptor Binding Domain (RBD, residues 330-530) as well as the human
angiotensin converting enzyme 2 (ACE2) receptor. Building upon our previous work, [**10**] models
were solvated and simulated using 'NAMDv2.14' software [**11**] for over 200 nanoseconds before
visual assessment of changes to surface epitopes and receptor binding interfaces. More modelling
details included in Supplementary Methods.

Statistical Analysis

NT_{50} values were analysed and expressed as Log base 2 (Log_2). The VNT data were grouped
based on vaccines, sex (female and male), and age groups (<35 – young; 35-60 – middle and >60 –
senior). Both one-way and two-way Analysis of Variance (ANOVA) were used to test the statistical
differences between vaccines, sex, age, day post vaccination/booster, variants, and their interactions.
If the ANOVA results returned a p-value of <0.05, a *post hoc* test with a Tukey's range test (Tukey's
Honestly Significant Difference, c.f. Supplementary Tables) was performed to measure the
interactions between two variables. Plots were drawn using '*ggplot2*' and modified in Adobe
Illustrator for clarity. All statistical procedures used the '*car*' and '*lme4*' libraries in R [**12**]. Fold
changes were calculated as: $2^{(Log_2 x - Log_2 y)}$.

Results and Discussion

Neutralisation of Delta and Omicron Variants of Concern

Table 1 shows the median ages for AstraZeneca sample donors are 57.5 compared to 38.5 for
Moderna, and 33 for Pfizer vaccine donors respectively, the reasons for which are as follows. The
Australian Technical Advisory Group on Immunisation (ATAGI) changed its recommendations
regarding the AstraZeneca vaccine following reports of thrombotic thrombocytopenia syndrome
(TTS) emerging from vaccinated adults [**13**]. It is worth noting that some individuals younger than 60
have received AstraZeneca vaccine following an assessment by a qualified health processional and
with a verbal or written consent as provisioned by the Department Health, Government of Australia
[**6**], but there is no brand preference for people aged 60 years and above because the benefits
outweigh the risk of TTS in this age group. As a result, samples predominantly originated from
young and middle-aged individuals for the Moderna and Pfizer vaccines, and from middle-aged and
senior adults for the AstraZeneca vaccine. Given the large age range for the Pfizer vaccine, for this
manuscript we classified the age groups in to young (<35 age), middle (35-60) and senior (>60). We
chose 35 as the cut-off for middle age as it generally corresponds to parents of teen aged children and
is used in metrics such as the Peterson-KFF health System Tracker [**14**] which has identified COVD-
19 as the second and third most important cause of death of people who are over and under 35,
respectively. In Australia, Moderna vaccine was approved for use relatively recently (9 August
2021), while a third dose of the AstraZeneca is only approved in exceptional circumstances, therefore
this study did not have access to third-dose samples for these vaccines.

Calculation of fold changes using the data presented in **Table 2** and **Figure 1**, demonstrate that
for the Pfizer vaccine there was an 8.2- and 5.5-fold reduction in NT_{50} titres against VIC31 and Delta
respectively 6 months after second dose administration (compared to two weeks), while the average
titre against Omicron decreased from an estimated 1:6.3 (only 4/15 samples had quantifiable
neutralization) to below assay detection limit for all samples at the same time points. Subsequently
there was a 25.5- and 24.6-fold increase in titres against VIC31 and Delta respectively two weeks
after a third dose administration (compared to 6 month post-second dose), while the average titre
against Omicron increased from below assay detection limit to 1:48.5 at the same time points.
Because of the aforementioned limitations, calculation of such fold changes for AstraZeneca and
Moderna were not possible. However, it is worthwhile to compare their neutralisation titres two
weeks post-second dose relative to the Pfizer vaccine samples. Across all three variants, we did not
find any significant difference between Pfizer and Moderna vaccines by 2nd week post second dose of
the vaccines (**Supplementary Table S1**).

ANOVA (one-way and two-way) was used to investigate the interactions of age, sex, vaccine,
and day post vaccination/booster with neutralising antibody titres to the three different virus variants.
One-way and two-way ANOVA analyses showed that, for all vaccines (Pfizer, Moderna and
AstraZeneca), day post vaccination/booster and virus variant were the main contributors to
differences in neutralising antibody responses, while age and sex did not have significant effects.
Based on ANOVA analysis there was no significant difference in neutralising titres based on age or
sex for any of the vaccines (**Supplementary Tables S2 & S3; Figure 2A-C**). The titres were
dependent on the vaccine, day post-vaccination and variant (p<0.001) and to an extent the age where
antibody titres in young showed statistically significant difference when compared to the middle and
senior age groups (p=0.022). The antibody titres against Omicron have a negative slope and
indicating that there is poor neutralisation with the variant.

Importance of Third Dose for Neutralisation of Omicron

In line with recent findings in similar studies by other groups [**15,16**], Omicron titres were
significantly lower than VIC31-D614G and Delta titres at all time points and regardless of vaccine,
highlighting the concern of poor protection to Omicron following vaccination by any of the three
leading vaccines. One shortcoming of our data is the lack of later samples and post-boost (third
vaccination) from individuals vaccinated with AstraZeneca and Moderna vaccines. However, the data
available from Pfizer vaccinated individuals at 6 months after receiving their second dose indicate a
significant waning of immunity to all three variants over this period. Neutralising antibody levels to
Omicron were low or undetectable in most individuals two weeks after receiving two Pfizer doses,
and below the assay limit of detection in all samples tested at 6 months after the second dose.
However, at two weeks after the booster vaccination (third Pfizer dose), a significant booster effect in
neutralising titres was noted to all three variants. This highlights the importance of the need for a
booster (third) vaccine dose for ongoing protection against D614G and Delta variants, but more
importantly that two doses are insufficient to stimulate significant neutralising protection against
Omicron BA.1, therefore making the third dose essential. The cause of better protection against
Omicron BA.1 following three doses of vaccine incorporating Spike protein lacking Omicron
specific mutations, is likely due to higher overall neutralising titres due to a booster effect despite
neutralising antibodies to certain epitopes being circumvented.

Modelling and Analyses using *in silico* methods

From structural perspectives, there are significantly more mutations in the Spike protein of the
Omicron variant shown in **Figure 4A**, (37 mutations in the BA.1 variant, 32 in the BA.2 variant
including insertions and deletions), compared to the Delta variant (10 mutations), while only one in
the VIC31 strain (D614G). The Omicron mutations contribute to its ability to circumvent vaccine or
infection induced neutralising antibody responses [**15,16**]. Three of these mutations (G142D, T478K
and D614G) are common to Delta and Omicron, however we have previously shown experimentally
and through *in silico* modelling that D614G has no significant impact on vaccines [**4**]. In the receptor
binding domain (RBD) of the Spike protein alone, which is most immunologically exposed in its 'up'
configuration and critical for ACE2 binding, there are 15 and 17 mutations in the Omicron BA.1 and
BA.2 variants compared to only 2 in Delta as shown in **Figures 4A & C**. Many of the observed
Omicron mutations by our analysis appear to be immune evasive, as they do not appear to be at the
ACE2 binding interface and represent a significant change in the residue characteristics; in the RBD,
these include N440K, K417N, S477N, T478K, and E484A.

Interestingly our isolate VIC28585 belongs to the BA.1.1 sub-lineage as it also contains the
R346K spike mutation, which possibly further decreases antibody neutralization based on the
reduced binding of class 2 antibodies in theoretical studies with the Mu variant of interest [**17**]. Next-
generation sequencing results also indicated the presence of additional Spike mutations S373P and
S375F in our VIC28585 isolate at frequency exceeding 99.8%; these two mutations with Grantham
scores of 74 (moderately conservative change) and 155 (radical change) respectively are near the
S371L Spike mutation characteristic to BA.1 which has a Grantham score of 145 (moderately radical
change; *n.b.* these three mutations are also present in EPI_ISL_7869197 mentioned below). Thus, we
have investigated the neutralising responses to Omicron BA.1.1 in individuals vaccinated with three
leading COVID-19 vaccines and compared these neutralising titres to those against an early SARS-
CoV-2 isolate with the D614G mutation (VIC31), and the Delta variant (B.1.617.2) that subsequently
became the dominant variant worldwide prior to Omicron's emergence. For example, on 11
December 2021 the ratio of Delta : BA.1 : BA.1.1 : BA.2 : Other in USA (where extensive data is
available from the CDC; [**18**]) was 92.5 : 5.2 : 2.2 : 0 : 0.2, and this steadily changed over two
months so that on 12 February 2021 the ratio was 0 : 22.9 : 73.2 : 3.9 : 0. This shows that BA.1.1,
used in our study, could emerge as the dominant variant although we need to wait for more
comprehensive data from around the world – as of 16 February 2022, 719,364 sequences of BA.1
were reported from 139 countries, while 410,015 sequences of BA.1.1 were reported from 127
countries.

Other Omicron mutations are likely to confer increased binding affinity to ACE2 by increasing
molecular interactions such as salt bridges and pi-stacking [**9**]; these mutations include Q493R and
Q498R (increasing salt bridge interactions with ACE2's D38 and E35) and N501Y (also seen in
Alpha, Beta and Gamma variants, pi-stacking with ACE2's Y41, shown in **Supplementary Figure**
S1. A cluster of mutations S371L, S373P and S375F, interestingly appear co-located with Y505H in
adjacent RBD domains in the 'down' position. These serine mutations, as well as significantly
altering epitope presentation of the RBD domain by creating a more rigid structural motif, may allow
H505 to interact with the adjacent F375, potentially modulating 'up'/'down' conformations via the
ionizable H505, (pK_a of 6.0). This structural change may coincide with the observed Omicron
preference of infection to the bronchus, where pH is usually lower at 5.5 to 6.5, compared to the lung
[**19**,**20**] (**Supplementary Figure S2**).

With the large number of mutations, it is unsurprising that the Omicron variant displays the
observed antibody evasion and replicative advantage over earlier variants [**21**], as experimentally
observed in our study. Our biomolecular modelling shows sufficient distinction between BA.1 and
BA.2, therefore future studies should experimentally compare the two.

Public Health Implications and Future Studies

The data we present here highlight the importance of booster vaccination for adequate
protection against newly emerging variants such as Omicron BA.1. Further studies are needed to
perform similar analyses of neutralising titres in individuals receiving "heterologous" booster doses,
e.g., initial AstraZeneca vaccination followed by Moderna or Pfizer boost, or Pfizer-Moderna /
Moderna-Pfizer.

In the early days of the pandemic, the scientific prediction was that SARS-CoV-2 will have a
mutation rate similar to SARS-CoV ($0.8\text{-}2.4\text{x}10^{-3}$) thanks to the 3′-to-5′ exoribonuclease
'proofreading mechanism' in coronaviruses [**22**], which was thought to result in a reduction in the
mutation rate ($\sim 10^{-6}$ per site per cycle) compared to influenza ($\sim 3\text{x}10^{-5}$ per site per cycle) [**23**,**24**].
Therefore, it was predicted that vaccine matching may not be required as frequently as seasonal
influenza (once a year each for Northern and Southern hemispheres), although this was hard to say
definitively because SARS-CoV-2's genetic drift was uncertain with respect to the long-lasting
efficacy of vaccine candidates then under development [**25**]. Early studies, for instance between 1
February to 1 May 2020 seemed to confirm the mutation rate prediction with a median estimate of
$1.12\text{x}10^{-3}$ per site-year ([**26**]; we believe their upper 95% confidence interval should read 1.85×10^{-3}).

Two years on, we have increasing evidence, including from this work, that the primary
immunization schedule should consist of three rather than two doses, and indeed many countries are
redefining 'fully vaccinated' status as three doses of these vaccines [**27**]. It is early to speculate on
annual boosters beyond the third dose, although Israel has started to expand its fourth dose
administration to groups beyond the immunocompromised [**28**,**29**]. These developments make it all
the more important to ensure vaccine equity across the world, so everyone is adequately protected
and highlight the potential need for vaccine matching to increase protection against infection.
Vaccines using Spike as the primary antigen should consider including mutations common to BA.1,
BA.1.1, and BA.2; development of vaccines with additional antigens, other than Spike, targeting
more conserved viral factors should also be explored. This view is further supported by a recent
preprint currently under peer review suggesting that, although a fourth dose restored anti-Omicron
BA.1 (EPI_ISL_7869197) neutralising antibody titres to a level observed post-third dose,
breakthrough Omicron infections were common with high virus titres, albeit with very mild clinical
signs [**29**,**30**].

In this context, it is important to explore vaccines that can better withstand mutations to the
Spike protein better, and ideally have less dependence on cold chain. In addition to repeating this
work with Omicron BA.2, it is also important to explore the benefits of T cell immunity and
heterologous boosting (which are beyond the scope of this paper; but see for instance these studies
[**31-34**]). Another aspect worth exploring is intranasal administration of selected vaccines. In the
earliest study (conducted from March 2020) looking at intranasal administration of the AstraZeneca
vaccine [**35**], we found that although neutralising antibody titres were 2-fold lower in ferrets
receiving two doses of this vaccine intranasally compared to the intramuscular route, the former was
more protected using virus shedding as an infection metric [**36**]. These findings were subsequently
confirmed in hamsters and non-human primates [**37**], and also reportedly led to a small clinical trial

in 30 humans [**38**]. We feel that the intranasal route, and the role of mucosal immunity, needs to be
explored more comprehensively given that the AstraZeneca vaccine has the widest reach (183
countries worldwide), with over 2.5 billion doses administered [**39**].

References

1. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E et al.
Coronavirus Pandemic (COVID-19) [Internet]. Our World in Data. 2020 [cited 20 February
2022]. Available from: https://ourworldindata.org/coronavirus
2. World Bank. *World Bank Country and Lending Groups* (2022). Available at:
https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-
lending-groups
3. WHO. *Tracking SARS-CoV-2 variants* (2022). Available at:
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
4. McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, Todd S, et al. Experimental and in
Silico Evidence Suggests Vaccines Are Unlikely to Be Affected by D614G Mutation in
SARS-CoV-2 Spike Protein. *npj Vaccines* (2020) 5(1):96. doi: 10.1038/s41541-020-00246-8.
5. Malladi SK, Patel UR, Rajmani RS, Singh R, Pandey S, Kumar S, et al. Immunogenicity and
Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding
Domain Derivative. *ACS Infectious Diseases* (2021) 7(8):2546-64. doi:
10.1021/acsinfecdis.1c00276.
6. Australian Government Department of Health. *Vaxzevria (AstraZeneca)* (2022). Available at:
https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-
vaccines/astrazeneca
7. Kärber G. Beitrag Zur Kollektiven Behandlung Pharmakologischer Reihenversuche. *Naunyn-*
Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie (1931) 162(4):480-
3. doi: 10.1007/BF01863914.
8. Sitaras I, Personal Communication (16 February 2022) to S.S. Vasan.
9. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly Accurate
Protein Structure Prediction with AlphaFold. *Nature* (2021) 596(7873):583-9. doi:
10.1038/s41586-021-03819-2.
10. Kuiper MJ, Wilson LOW, Mangalaganesh S, Lee C, Reti D, Vasan SS. "But Mouse, You Are
Not Alone": On Some Severe Acute Respiratory Syndrome Coronavirus 2 Variants Infecting
Mice. *ILAR Journal* (2022). doi: 10.1093/ilar/ilab031.
11. Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, et al. Scalable
Molecular Dynamics on Cpu and Gpu Architectures with Namd. *J Chem Phys* (2020)
153(4):044130. doi: 10.1063/5.0014475.
12. R-Core-Team. *R: A Language and Environment for Statistical Computing*; R Foundation for
Statistical Computing: Vienna, Austria, 2019. Available online: https://www.r-project.org/
13. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
Thrombocytopenia after Chadox1 Ncov-19 Vaccination. *New England Journal of Medicine*
(2021) 384(22):2092-101. doi: 10.1056/NEJMoa2104840.
14. Peterson-KFF Health System Tracker. *COVID-19 leading cause of death ranking* (2022).
Available at: https://www.healthsystemtracker.org/
15. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma
Neutralization of the SARS-CoV-2 Omicron Variant. *New England Journal of Medicine*
(2021) 386(6):599-601. doi: 10.1056/NEJMc2119641.

16. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant
Neutralization in Serum from Vaccinated and Convalescent Persons. *New England Journal of*
Medicine (2022) 386(7):698-700. doi: 10.1056/NEJMc2119236.
17. Fratev F. R346k Mutation in the Mu Variant of SARS-CoV-2 Alters the Interactions with
Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study. *Journal of*
Chemical Information and Modeling (2022) 62(3):627-31. doi: 10.1021/acs.jcim.1c01243.
18. CDC. *COVID Data Tracker* (2022). Available at: https://covid.cdc.gov/covid-data-
tracker/#datatracker-home
19. Hui KPY, Ho JCW, Cheung M-c, Ng K-c, Ching RHH, Lai K-l, et al. SARS-CoV-2 Omicron
Variant Replication in Human Bronchus and Lung Ex Vivo. *Nature* (2022). doi:
10.1038/s41586-022-04479-6.
20. Fischer H, Widdicombe JH. Mechanisms of Acid and Base Secretion by the Airway
Epithelium. *J Membr Biol* (2006) 211(3):139-50. Epub 20061107. doi: 10.1007/s00232-006-
0861-0.
21. Liu L, Iketani S, Guo Y, Chan JFW, Wang M, Liu L, et al. Striking Antibody Evasion
Manifested by the Omicron Variant of SARS-CoV-2. *Nature* (2021). doi: 10.1038/s41586-
021-04388-0.
22. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, et al. Moderate Mutation Rate in the
Sars Coronavirus Genome and Its Implications. *BMC Evol Biol* (2004) 4:21. Epub 20040628.
doi: 10.1186/1471-2148-4-21.
23. Bar-On YM, Flamholz A, Phillips R, Milo R. SARS-CoV-2 (Covid-19) by the Numbers.
eLife (2020) 9:e57309. doi: 10.7554/eLife.57309.
24. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral Mutation Rates. *J Virol*
(2010) 84(19):9733-48. Epub 20100721. doi: 10.1128/jvi.00694-10.
25. Bauer DC, Tay AP, Wilson LOW, Reti D, Hosking C, McAuley AJ, et al. Supporting
Pandemic Response Using Genomics and Bioinformatics: A Case Study on the Emergent
SARS-CoV-2 Outbreak. *Transbound Emerg Dis* (2020) 67(4):1453-62. doi:
https://doi.org/10.1111/tbed.13588.
26. Koyama T, Platt D, Parida L. Variant Analysis of SARS-CoV-2 Genomes. *Bull World Health*
Organ (2020) 98(7):495-504. Epub 2020/06/02. doi: 10.2471/BLT.20.253591.
27. Australian Government Department of Health. ATAGI statement on defining 'up-to-date'
status for COVID-19 vaccination (2022). Available at: https://www.health.gov.au/news/atagi-
statement-on-defining-up-to-date-status-for-covid-19-vaccination
28. Burki TK. Fourth Dose of Covid-19 Vaccines in Israel. *The Lancet Respiratory Medicine*
(2022) 10(2):e19. doi: 10.1016/S2213-2600(22)00010-8.
29. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. 4th Dose
Covid mRNA Vaccines' Immunogenicity & Efficacy against Omicron VOC. *medRxiv*
(2022):2022.02.15.22270948. doi: 10.1101/2022.02.15.22270948.
30. Mandelboim M, Personal Communication (22 February 2022) to S.S. Vasan.
31. May DH, Rubin BER, Dalai SC, Patel K, Shafiani S, Elyanow R, et al. Immunosequencing
and Epitope Mapping Reveal Substantial Preservation of the T Cell Immune Response to
Omicron Generated by SARS-CoV-2 Vaccines. *medRxiv* (2021):2021.12.20.21267877. doi:
10.1101/2021.12.20.21267877.
32. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. SARS-CoV-2 Spike
T Cell Responses Induced Upon Vaccination or Infection Remain Robust against Omicron.
medRxiv (2021):2021.12.26.21268380. doi: 10.1101/2021.12.26.21268380.

33. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al.
Homologous and Heterologous COVID-19 Booster Vaccinations. *New England Journal of*
Medicine (2022). doi: 10.1056/NEJMoa2116414.
34. He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. Heterologous Prime-Boost: Breaking the
Protective Immune Response Bottleneck of COVID-19 Vaccine Candidates. *Emerg Microbes*
Infect (2021) 10(1):629-37. doi: 10.1080/22221751.2021.1902245.
35. Jayaraman KS. Ferret Chosen as Animal Model to Test Coronavirus Vaccines. *Nature India*
(5 April 2020). Available at: http://go.nature.com/39LGAqx.
36. Marsh GA, McAuley AJ, Au GG, Riddell S, Layton D, Singanallur NB, et al. ChAdOx1
nCoV-19 (AZD1222) Vaccine Candidate Significantly Reduces SARS-CoV-2 Shedding in
Ferrets. *npj Vaccines* (2021) 6(1):67. doi: 10.1038/s41541-021-00315-6.
37. Van Doremalen N, Purushotham Jyothi N, Schulz Jonathan E, Holbrook Myndi G,
Bushmaker T, Carmody A, et al. Intranasal ChAdOx1 nCov-19/AZD1222 Vaccination
Reduces Viral Shedding after SARS-CoV-2 D614G Challenge in Preclinical Models. *Science*
Translational Medicine (2021) 13(607):eabh0755. doi: 10.1126/scitranslmed.abh0755.
38. Imperial College London. *Landmark coronavirus study to trial inhaled Imperial and Oxford*
vaccines (2020). Available at: https://www.imperial.ac.uk/news/203653/landmark-
coronavirus-study-trial-inhaled-imperial/
39. BBC. *AstraZeneca vaccine: Did nationalism spoil UK's 'gift to the world'?* (2022). Available
at: https://www.bbc.com/news/health-60259302
40. Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically
disordered proteins. *Nature Methods* (2017) 14, 71-73, doi:10.1038/nmeth.4067
41. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Science (2020) 367, 1260-1263 doi: 10.1126/science.abb2507
42. Watanabe Y, Allen, JD, Wrapp, J, McLellan, JS, Crispin, M. Site-specific glycan analysis of
the SARS-CoV-2 spike *Science* (2020) 369(6501):330-333. doi: 10.1126/science.abb9983.
43. Humphrey, W., Dalke, A. and Schulten, K., "VMD - Visual Molecular Dynamics", *J. Molec.*
Graphics, 1996, vol. 14, pp. 33-38.41

Figures 1-4

Figure 1: Box Plots Showing 50% Neutralisation Titres (NT_{50}) Against SARS-CoV-2 Variants
of Concern with Plasma from Human Volunteers

Neutralisation of VIC31, Delta, and Omicron by human donor samples collected at different
timepoints following vaccination with AstraZeneca (A), Moderna (B), or Pfizer (C) COVID-19
vaccines.

Figure 2: Box Plots Showing 50% Neutralization Titres (NT$_{50}$) Against SARS-CoV-2 Variants of Concern Assessed by Sex of Donors

Plasma samples from human volunteers vaccinated with either AstraZeneca (A), Moderna (B), or Pfizer (C) vaccines were tested in neutralisation assays against VIC31 (i), Delta (ii), and Omicron (iii), with titres assessed with respect to sex.

Figure 3: Box Plots Showing NT$_{50}$ Values Against SARS-CoV-2 Variants of Concern Assessed by Age Group

Plasma samples from human volunteers vaccinated with either AstraZeneca (A), Moderna (B), or Pfizer (C) vaccines were tested in neutralisation assays against VIC31 (i), Delta (ii), and Omicron (iii), with titres assessed with respect to age group.

Figure 4: Structure of SARS-CoV-2 Spike Protein and Mutations of Interest

A. The Omicron spike protein with mutations shown in pink. A single S1 domain is highlighted in blue with the receptor binding domain (RBD) in the 'up' configuration is highlighted in cyan. Glycosylation is shown as green lines. **B.** & **C.** Comparison of the RBD in the Omicron and Delta variants, 15 mutations are observed in Omicron while only 2 in the Delta variant.

445 **Tables 1 & 2**

446 **Table 1**: **Information on Human Participants, Vaccines, and Blood Collection Schedule**

		AstraZeneca	Moderna	Pfizer
Donor		n=6	n=12	n=15
Sex	Male	n=3	n=6	n=5
	Female	n=3	n=6	n=10*
Age	Male	58 (57-65)	41.5 (29-70)	31 (29-35)
[Median (Range)]	Female	57 (31-59)	38.5 (27-47)	33.5 (25-57)
	Overall	57.5 (31-65)	38.5(27-70)	33 (25-57)
	pre-1st Dose	n=6 (3M, 3F)	n=12 (6M, 6F)	n=15 (5M, 10F)
Samples Used	2w Post-2nd Dose	n=6 (3M, 3F)	n=12 (6M, 6F)	n=15 (5M, 10F)
	6mo Post-2nd Dose			n=15 (5M, 10F)
	2w Post-3rd Dose			n=6 (3M, 3F)

447 *For pre-1st dose and 2w post-2nd dose the samples are gender balanced.

449 **Table 2: Sex-Based Mean and Standard Deviation for VNT Titres Against SARS-CoV-2**
450 **Variants for Human Subjects Vaccinated with Different COVID-19 Vaccines.**

Vaccine	Sex	Estimates	VIC31				Delta				Omicron			
			1	2	3	4	1	2	3	4	1	2	3	4
AstraZeneca	Female	Mean	2.32	3.46	X	X	2.32	2.32	X	X	2.32	2.32	X	X
		SD	0.00	0.00	X	X	0.00	0.00	X	X	0.00	0.00	X	X
	Male	Mean	2.32	5.04	X	X	2.32	2.82	X	X	2.32	2.32	X	X
		SD	0.00	1.01	X	X	0.00	0.86	X	X	0.00	0.00	X	X
	All	Mean	2.32	4.25	X	X	2.32	2.57	X	X	2.32	2.32	X	X
		SD	0.00	1.08	X	X	0.00	0.61	X	X	0.00	0.00	X	X
Moderna	Female	Mean	2.32	7.16	X	X	2.32	5.99	X	X	2.32	2.57	X	X
		SD	0.00	1.11	X	X	0.00	0.76	X	X	0.00	0.61	X	X
	Male	Mean	2.32	6.93	X	X	2.32	5.05	X	X	2.32	2.82	X	X
		SD	0.00	1.17	X	X	0.00	1.28	X	X	0.00	0.80	X	X
	All	Mean	2.32	7.04	X	X	2.32	5.52	X	X	2.32	2.69	X	X
		SD	0.00	1.09	X	X	0.00	1.12	X	X	0.00	0.69	X	X
Pfizer	Female	Mean	2.32	7.22	3.75	7.93	2.32	6.36	3.37	7.39	2.32	2.73	2.32	4.59
		SD	0.00	1.08	0.66	0.38	0.00	1.04	0.79	0.51	0.00	0.67	0.00	0.71
	Male	Mean	2.32	6.76	4.61	9.49	2.32	5.76	4.34	9.27	2.32	2.49	2.32	6.63
		SD	0.00	0.92	0.71	0.67	0.00	1.06	0.97	0.77	0.00	0.38	0.00	1.17
	All	Mean	2.32	7.07	4.04	8.71	2.32	6.15	3.70	8.32	2.32	2.65	2.32	5.60
		SD	0.00	1.02	0.78	0.98	0.00	1.05	0.95	1.19	0.00	0.59	0.00	1.40

All VNT titres expressed as Log2 values. Values indicated as 2.32 represent titres below the assay detection limit. SD =
Standard Deviation of Mean; 1 =-1st dose; 2 = 2wk-2nd dose; 3 = 6mo-2nd dose and 4 = 2wk-3rd dose. X = sample not
available for analysis

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material.
Further inquiries can be directed to the corresponding author.

Ethics Statement

The study protocols were approved by institutional ethics committees of the Peter Doherty Institute,
Melbourne Australia [University of Melbourne Central Human Research Ethics Committee (2021-
21198-15398-3)] and the CSIRO (CSIRO Human Research Ethics Committee ID 2021_123_RR).
The reference serum for the neutralisation assay was derived from an animal study reviewed and
approved by CSIRO ACDP Animal Ethics Committee (AEC 2004).

Author Contributions

NBS designed the study with PJvV, AJM, SMG and SSV. PJvV and AJM performed the experiments
with MPB, SR and SG. NBS and SMG analysed the experimental data and provided statistical
interpretations, with inputs from PJvV, AJM, TWD and SSV. MJK performed biomolecular
modelling and provided structural interpretations. LC and JDD isolated the virus variants, which
were sequenced by KRB and MT. JAJ, SJK and AKW provided the human plasma samples and
obtained the necessary funding for the same. SM, SC and SSV analysed the health economic
implications. NBS, PJvV, AJM, MJK, SM, SC and SSV co-wrote the manuscript, and all authors
contributed to revisions and creation of the final version. SV conceived the conceived the project and
obtained funding.

Funding

This work was supported by funding (Principal Investigator: S.S.V.) from the CSIRO's Precision
Health & Responsible Innovation Future Science Platforms, National Health and Medical Research
Council (grant MRF2009092), and United States Food and Drug Administration (FDA) Medical
Countermeasures Initiative (contract 75F40121C00144). J.A.J., S.J.K. and A.K.W. are grateful to the
National Health and Medical Research Council (for grants GNT2002073, MRF2005544,
GNT1149990, fellowships and an investigator grant). We also thank the Victorian Government,
especially the Victorian Department of Health and Human Services, the major funder of the Victorian
Infectious Diseases Reference Laboratory and Barwon Health. The article reflects the views of the
authors and does not represent the views or policies of the funding agencies including the FDA.

Conflict of Interest

All claims expressed in this article are solely those of the authors and do not necessarily represent
those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any
product that may be evaluated in this article, or claim that may be made by its manufacturer, is not
guaranteed or endorsed by the publisher.

Acknowledgments

The authors are grateful for support from Professor Sharon Lewin, Professor Deborah Williamson
and colleagues at the Peter Doherty Institute for Infection and Immunity
(https://www.grid.ac/institutes/grid.483778.7); the CSIRO eHealth programme (particularly Drs
Laurence Wilson and Carol Lee); and the CSIRO's Australian Centre for Disease Preparedness

(ACDP; https://www.grid.ac/institutes/grid.413322.5), especially Dr Daniel Layton and Kristen
McAuley. We thank Dr Amy Shurtleff of the Coalition for Epidemic Preparedness Innovations and
the University of Oxford's Professors Teresa Lambe and Dame Sarah Gilbert for access to positive
control ferret sera from their study (CSIRO ACDP Animal Ethics Committee Approval Reference:
AEC 2004).

Supplementary Material

Supplementary Tables S1 to S3

Supplementary Table S1: Comparison for NT50 values on 2nd-2wk

Comparison	Variant	Estimate ('adjusted' p-value)
Pfizer vs Moderna	VIC31	p > 0.100
Pfizer vs Moderna	Omicron	p > 0.100
Pfizer vs Moderna	Delta	p > 0.100

502 **Supplementary Table S2: One-way ANOVA results for vaccines, variants, sex, age and day**
503 **post vaccination/boosters**

Vaccine	Variable	F-value	p-value	Tukey's HSD post hoc Comparison ('adjusted' p-value)
Pfizer	Sex	2.421	>0.100	No significant difference
	Age	0.859	>0.100	No significant difference
	Day post vaccination/booster	73.84	<0.0001	Pre 1st Dose – 2wk Post-2nd Dose p < 0.0001 Pre 1st Dose – 6mo Post-2nd Dose p < 0.01 Pre 1st Dose – 2wk Post-3rd Dose p < 0.0001 2wk Post 2nd Dose – 6mo Post-2nd Dose p < 0.0001 2wk Post 2nd Dose – 2wk Post-3rd Dose p < 0.0001 6mo Post 2nd Dose – 2wk Post-3rd Dose p < 0.0001
	Variant	16.61	<0.0001	Delta – Omicron p < 0.0001 VIC31 – Omicron p < 0.0001
Moderna	Sex	0.104	>0.100	No significant difference
	Age	0.074	>0.100	No significant difference
	Day post vaccination/booster	64.56	<0.0001	Pre 1st Dose – 2wk Post-2nd Dose p < 0.0001
	Variant	8.839	<0.001	Delta – Omicron p < 0.05 VIC31 – Omicron p < 0.001
AstraZeneca	Sex	1.497	>0.100	No significant difference
	Age	1.401	>0.100	No significant difference
	Day post vaccination/booster	7.722	<0.01	Pre 1st Dose – 2wk Post-2nd Dose p < 0.01
	Variant	5.744	<0.01	VIC31 – Delta p < 0.05 VIC31 – Omicron p < 0.05

508 **Supplementary Table S3: Two-way ANOVA results of interactions for vaccines, variants, sex,**
509 **age and day post vaccination/boosters**

Vaccine	Factor 1	Factor 2	F-Value	p-Value	Tukey's HSD post hoc Comparison ('adjusted' p-value)
		Sex	0.047	>0.100	No significant difference
		Age	0.018	>0.100	No significant difference
Pfizer	Variant	Day post vaccination/booster	26.31	$<0.0001^{\dagger}$	Pre 1st Dose – 2wk Post-2nd Dose p < 0.0001 Pre 1st Dose – 6mo Post-2nd Dose p < 0.0001 Pre 1st Dose – 2wk Post-3rd Dose p < 0.0001 2wk Post 2nd Dose – 6mo Post-2nd Dose p < 0.0001 2wk Post 2nd Dose – 2wk Post-3rd Dose p < 0.0001 6mo Post 2nd Dose – 2wk Post-3rd Dose p < 0.0001 Delta – Omicron p < 0.0001 VIC31 – Omicron p < 0.0001
		Sex	0.158	>0.100	No significant difference
		Age	0.052	>0.100	No significant difference
Moderna	Variant	Day post vaccination/booster	59.91	$<0.0001^{\dagger}$	Pre 1st Dose – 2wk Post-2nd Dose p < 0.0001 Delta – Omicron p < 0.05 VIC31 – Omicron p < 0.001
		Sex	0.872	>0.100	No significant difference
		Age	0.507	>0.100	No significant difference
AstraZeneca	Variant	Day post vaccination/booster	13.00	$<0.0001^{\dagger}$	Pre 1st Dose – 2wk Post-2nd Dose p < 0.01 Delta – Omicron p < 0.05 VIC31 – Omicron p < 0.05

510 †In two-way ANOVA the main effect for variant was statistically significant (p < 0.0001). However, the interaction
511 effects of variant with age or sex were not statistically significant (p > 0.05) but there were statistically significant
512 interactions between the effects of variant and day post vaccination/booster (p < 0.001).

514
515

516 **Supplementary Methods**
517
518 **Statistical analysis using linear mixed models**
519
Linear Mixed Models (*lm* and *lmer*) analyses were used to investigate the interactions of age,
sex, vaccine, and day post vaccination/booster with neutralising antibody titres to the three different
virus variants using '*lme4*' library in R [**12**]. To avoid, over fitting of data, we are not showing the
results of *lm* and *lme* analyses. One-way and two-way ANOVA analyses showed that, for all
vaccines (Pfizer, Moderna and AstraZeneca), day post vaccination/booster and virus variant were the
main contributors to differences in neutralising antibody responses, while age and sex did not have
significant effects.
527

Linear Mixed Model analysis of the variance between variables (results not shown) confirmed
the ANOVA analyses which showed that day post vaccination/booster and virus variant are the major
contributors to titre differences, but further shows that there was a significant difference in
neutralising titres elicited by the three different vaccines, mostly due to poor responses to the
AstraZeneca vaccine. This analysis model further suggests that younger individuals (aged less than
35 years) are likely to have a stronger neutralising antibody response than older individuals, but we
concede that this finding might be confounded by the distribution of the ages within the vaccine
groups. This might also explain the poorer responses in the AstraZeneca group because of the
vaccine advice in Australia (AstraZeneca mostly used in the older age group).

Modelling using *in silico* methods

Molecular simulations were performed using NAMD2.14 with CHARM36m forcefield [**40**]
employing a TIP3 water model. The Spike model was based on the pdb structure 6VSB3 [**41**], built
with additions segments predicted with AlphaFold. The Spike protein only included residues 13 to
1160 (omitting transmembrane domain, to reduce the simulation size). Glycosylation of the Spike
protein was manually constructed using Visual Molecular Dynamics (VMD) guided by glycan
analysis [**42**]. Omicron models were constructed in two conformations, all RBD 'down', and 2 RBD
'down' one RBD 'up'. Both models included an ACE2 domain in the expected binding position.

Simulations were run with Periodic Boundary Conditions 'PBCs' using the NPT ensemble at
310K and 1 bar pressure employing Langevin dynamics. The PBCs were constant in the XY
dimensions. Long-range Coulomb forces were computed with the Particle Mesh Ewald method with
a grid spacing of 1 Å. 2 fs timesteps were used with non-bonded interactions calculated every 2 fs
and full electrostatics every 4 fs while hydrogens were constrained with the 'SHAKE' algorithm. The
cut-off distance was 12 Å with a switching distance of 10 Å and a pair-list distance of 14 Å. Pressure
was controlled to 1 atmosphere using the NoséHoover Langevin piston method employing a piston
period of 100 fs and a piston decay of 50 fs. Trajectory frames were captured every 100 ps.
Simulations were performed for at least 200 nanoseconds. Trajectories were visualized and analysed
using VMD [**43**].

Supplementary Figures
557
558

559
560
561
562

563 **Supplementary Figure S1.** a) Omicron spike protein binding to ACE2 domain (shown in yellow).
564 S1 domain shown in blues, with the receptor binding domain shown in cyan. Glycosylation is shown
565 as green sticks. b) close up of the ACE2 binding interface of Omicron spike RBD showing the
566 interaction of contacting residues.

568
569 **Supplementary Figure S2.** Close up of Omicron mutations in adjacent receptor binding domains
570 (pink and blue) in 'down' position showing the close proximity of residues L371, P373 and F375 on
571 the blue domain to the adjacent H505. This complementary arrangement may have influence on the
572 RBD 'up'/'down' transitions by pH dependant ionization of H505.